Physician profile
Kathryn Stackhouse
NPI 1811382443
$2,551.38
in general payments reported to CMS, 2019-2025
15 companies · $241 in 2025
The $241 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $50.44 · 2022: $1,237 · 2023: $377 · 2024: $646 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,263.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,105.52 | 2022 | |
| Dilon Technologies, INC. | $668.26 | 2023-2025 | Hemoblast Bellows |
| Abbvie INC. | $153.75 | 2023-2025 | |
| Teleflex LLC | $105.25 | 2022 | |
| Ethicon US, LLC | $94.12 | 2024 | Echelon Endopath, Evarrest, Ethicon |
| Vivus LLC | $88.33 | 2023 | Qsymia |
| Glaxosmithkline, LLC. | $62.56 | 2024 | Jemperli, Zejula |
| Foundation Medicine, INC. | $55.78 | 2023 | |
| Davol INC. | $50.44 | 2020 | |
| Boston Scientific Corporation | $41.10 | 2024 | Spyglass Discover |
| Medtronic, INC. | $28.06 | 2025 | Signia |
| Integra Lifesciences Corporation | $26.42 | 2022 | |
| Merck Sharp & Dohme LLC | $26.09 | 2024 | Keytruda |
| Eisai INC. | $24.99 | 2024 | |
| Genmab U.S., INC. | $20.71 | 2024 | Tivdak |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Stackhouse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.